title: Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing.
abstract: Recombinant granulocyte/macrophage-colony-stimulating factor (rGM-CSF), prepared from Chinese hamster ovary (CHO) cells and Escherichia coli, was administered to 35 patients with the borderline and polar lepromatous forms of leprosy by the intradermal and subcutaneous routes at doses of 7.5-45.0 micrograms/d for 10 d. With each of these doses and routes, increases in the number of circulating eosinophils were noted. After the intradermal injection, the local skin sites demonstrated zones of roughening and micronodularity that appeared within 24-48 h and persisted for more than 6 d. Reinjection of sites led to enhanced areas of epidermal reaction. GM-CSF prepared from CHO cells was a more potent inducer of this effect. GM-CSF given by the subcutaneous route, at higher doses, failed to initiate these changes. At the microscopic level, the epidermis became thickened (+75%) with increased numbers and layers of enlarged keratinocytes. These contained increased numbers of ribosomes and prominent nucleoli, and were imbedded in a looser meshwork of the zona Pellucida. The modified keratinocytes remained MHC class II antigen negative throughout the course of the response. A major change in the dermis was the progressive accumulation of CD1+, Birbeck granule-positive cells. These Langerhans were recognizable at 48 h after intradermal injection and reached maximum numbers by 4 d. During this period the number of epidermal Langerhans cells remained relatively constant. No increment in dermal Langerhans cells occurred when GLM-CSF was injected by the subcutaneous route. No appreciable increase in the numbers of T cells and monocytes was noted, and granulocytes and eosinophils were largely present within the dermal microvasculature. 4-mm punch biopsies taken from injected sites and adjacent controls were compared in terms of the rapidity of wound healing. 22 of 26 sites demonstrated more rapid filling and hemostasis, whereas four were equivalent to controls. We conclude that rGM-CSF, when introduced into the skin, leads to enhanced keratinocyte growth, the selective recruitment of Langerhans cells into the dermis, and enhanced wound healing of the prepared site. There was no evidence of an enhanced cell-mediated response to Mycobacterium leprae, and bacillary numbers remained unchanged.
authors.affiliation: Laboratory of Cellular Physiology and Immunology, Rockefeller University, New York, New York 10021.
authors.forename: G
authors.initials: G
authors.lastname: Kaplan
authors.forename: G
authors.initials: G
authors.lastname: Walsh
authors.forename: L S
authors.initials: LS
authors.lastname: Guido
authors.forename: P
authors.initials: P
authors.lastname: Meyn
authors.forename: R A
authors.initials: RA
authors.lastname: Burkhardt
authors.forename: R M
authors.initials: RM
authors.lastname: Abalos
authors.forename: J
authors.initials: J
authors.lastname: Barker
authors.forename: P A
authors.initials: PA
authors.lastname: Frindt
authors.forename: T T
authors.initials: TT
authors.lastname: Fajardo
authors.forename: R
authors.initials: R
authors.lastname: Celona
mesh_terms: D000293:Adolescent; D000328:Adult; D000818:Animals; D016466:CHO Cells; D006224:Cricetinae; D004926:Escherichia coli / Q000235:genetics; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage / Q000235:genetics / Q000627:therapeutic use*; D006801:Humans; D007271:Injections, Intradermal; D007279:Injections, Subcutaneous; D015603:Keratinocytes / Q000187:drug effects / Q000473:pathology* / Q000502:physiology; D007801:Langerhans Cells / Q000187:drug effects / Q000473:pathology / Q000502:physiology*; D015439:Leprosy, Borderline / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D015440:Leprosy, Lepromatous / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D007962:Leukocytes / Q000187:drug effects / Q000502:physiology*; D008297:Male; D008854:Microscopy, Electron; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D012867:Skin / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology* / Q000648:ultrastructure; D013997:Time Factors; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D011994:Recombinant Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor